Senvelgo Oral Solution for Cats

Senvelgo Oral Solution is the first and only FDA-approved SGLT2 (sodium-glucose co-transporter 2) inhibitor specifically developed for cats. This innovative treatment is designed to manage chronic kidney disease (CKD)—a progressive condition commonly affecting aging felines. CKD can cause increased thirst and urination, weight loss, reduced appetite, and a general decline in overall health.

Senvelgo contains velagliflozin, which works by inhibiting the SGLT2 protein in the kidneys. This action reduces the reabsorption of glucose and sodium, helping to lower urinary protein levels (proteinuria)—a key contributor to kidney damage. By targeting this pathway, Senvelgo helps preserve kidney function and improves quality of life in cats with CKD.

Veterinary supervision is recommended during treatment to assess response and adjust dosing if necessary. Monitoring typically includes bloodwork, urinalysis, and evaluation of hydration, glucose levels, and kidney function.

Senvelgo offers a stress-free, once-daily oral solution—ideal for cats who may resist tablets or capsules. It represents a significant advancement in feline nephrology by helping to slow disease progression while enhancing comfort and well-being.

• Dosing easier – simple oral once-daily dosing, with minimal risk of clinical hypoglycemic events
• Stabilization quicker– provides effective glycemic control within 7 days for most cats, with no dose adjustments necessary
• Monitoring simpler – less monitoring and diagnostics are required for stabilized cats on SENVELGO oral solution